Reports

Impact of President's Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection

Milliman analyzes the impact of the proposed rule to implement point of sale rebates in Medicare Part D.
Download Report

Authors

Originally published on 03/08/2019

The analysis used claims data and drug class-specific rebates to help understand the implications of proposals to restructure parts of Medicare Part D overall, and by important categories of drugs including those for diabetes, cancer, and Hepatitis C.

Findings include that the implementation of POS rebates would reduce total costs to beneficiaries on high cost medications in exchange for modest net increases in premiums for all others. At our request, Milliman estimated the impact of an approach to POS rebates in which the pharmaceutical corporations continue to contribute funding at the same level as they do today, by implementing a separate true-out-of-pocket (TrOOP) accumulator for manufacturers based on the drug "list price" rather than the net-of-rebate price. Under 100% POS rebates in Part D, this change, which essentially maintains the status quo, restores $50B in funding to Part D over the next decade. Drug category specific analyses show the feasibility of a demonstration of POS rebates only for diabetics or cancer patients, and how much these patients would save under a 100% POS model.

 

Share

Authors

Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

Association of Rebates in Part D with Patient OOP and…
The way Medicare Part D's benefit design shows that rebates actually increase patients' out-of-pocket costs while shifting spending from plan sponsors and manufacturers to Medicare.
JAMA Internal Medicine 05/30/2017
The Conflict Between QALYs and Well-Funded Patient Advocacy Groups
The goal of a QALY is to figure out how much any given drug is worth to a society so that we, as a society, have a benchmark to evaluate the price of pharmaceutical products.
Relentless Health Value 12/10/2020
Remdesivir Less Expensive for "Government Programs"? Not So Fast.
Two options are proposed if Gilead wishes to offer the discounts to the full array of government programs.
Drug Pricing Lab 07/01/2020
Blueprints for Indication-Specific Pricing
Several approaches that rewire existing reimbursement conventions as alternatives to facilitate ISP are proposed.
Drug Pricing Lab 05/19/2020
Pharmaceutical Products and Their Value
Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.
Value in Health 03/29/2020
Drop in Cancer Deaths Reflect Failures of Our Society. Really.
Despite declining cancer death rates, the nation still presents societal failures to improve the state of our population's health.
The Boston Globe 02/21/2020
Dissecting PhRMA's Opposition to H.R. 3 Lower Drug Costs Now…
Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019.
STAT News 10/11/2019
Time to Throw in the Towel on Biosimilars
Peter Bach and Mark Trusheim of MIT Sloan School of Management underscore the drawbacks of Washington's preferred solution to introduce competition for biologics, the biosimilar model.
The Wall Street Journal 08/21/2019
Mortgaging New Treatments Kicks the Can on High Drug Prices
The launch price for one-time gene therapy Zolgensma presents various implications.
Morning Consult 07/09/2019
A $475,000 price tag for a new cancer drug: crazy…
Drug Pricing Lab op-ed in STAT News discusses indication-specific pricing of Kymriah.
STAT News 08/31/2017
US Drug Prices And R&D, Take 2: A Reply To…
To answer Health Affairs responses, Peter Bach and Nancy Yu point back to the research, emphasizing the original intent of the conservative R&D cost assumptions.
Health Affairs Blog 07/27/2017
Prevalence of Off-Label Use and Spending Among Patent-Protected Chemotherapies
The prevalence of off-label anticancer drug use is not well characterized.
JCO 02/19/2013

Featured News

See All News
Bloomberg Opinion 07/16/2020

Before Spending Billions, U.S. Hospitals Need to Study Remdesivir Further

As COVID-19 continually evolves and new therapies are approved and administered individually and in combination, the best way to apply scientific principle is to continue to test each treatment separately and together, beginning with Remdesivir.
Read Article
Newsletter

Stay up to date on our work and news